Agreements

* On July 9, 2013, Helsinn and Advancell have announced a partnering agreement for the development and worldwide commercialization of ATH008, a new topical product for the prevention and/or treatment of palmoplantar erythrodysesthesia syndrome, (caused for example by fluoropyrimidinesbased chemotherapy) and of hand-foot skin reactions, (caused for example by multitargeted kinase inhibitors, MKIs). Under the terms of the agreement, Helsinn will receive a worldwide exclusive license to ATH008 and will be responsible for all further development, regulatory approval, manufacturing, marketing and sales either on its own or through its sub-licensees. In return the Swiss Group will pay Advancell development milestones and sales royalties for an undisclosed amount. Advancell has applied its knowledge in the 

development area and formulation optimization to develop ATH008. The pre-clinical and clinical studies conducted so far suggest that ATH008 may be a safe and effective agent for the prevention and/or treatment of dermatological injuries caused by chemotherapy treatment, resulting in a reduction in the incidence and severity of these diseases.